Alimera Sciences (NASDAQ:ALIM) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Alimera Sciences (NASDAQ:ALIM) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently weighed in on the stock. HC Wainwright cut shares of Alimera Sciences from a buy rating to a neutral rating and set a $6.00 price target for the company. in a report on Tuesday, June 25th. Alliance Global Partners reiterated a neutral rating on shares of Alimera Sciences in a report on Tuesday, June 25th. Finally, Maxim Group reaffirmed a hold rating on shares of Alimera Sciences in a research report on Tuesday, June 25th.

Alimera Sciences Price Performance

ALIM opened at $5.56 on Friday. The stock has a market cap of $291.28 million, a P/E ratio of -3.54 and a beta of 1.25. Alimera Sciences has a 12 month low of $2.61 and a 12 month high of $5.65. The company has a quick ratio of 2.62, a current ratio of 2.79 and a debt-to-equity ratio of 1.80. The company has a fifty day simple moving average of $5.56 and a 200 day simple moving average of $4.29.

Alimera Sciences (NASDAQ:ALIM) last posted its earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Alimera Sciences had a negative net margin of 14.74% and a negative return on equity of 33.70%. The business had revenue of $27.00 million during the quarter, compared to analyst estimates of $25.76 million. On average, research analysts expect that Alimera Sciences will post -0.13 EPS for the current year.

Institutional Trading of Alimera Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Deltec Asset Management LLC acquired a new position in shares of Alimera Sciences during the 2nd quarter worth approximately $690,000. Vanguard Group Inc. grew its position in shares of Alimera Sciences by 61.1% in the 1st quarter. Vanguard Group Inc. now owns 1,045,460 shares of the biopharmaceutical company’s stock valued at $4,077,000 after acquiring an additional 396,506 shares during the period. Ancora Advisors LLC acquired a new position in shares of Alimera Sciences during the 1st quarter worth about $915,000. Fifth Lane Capital LP bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $83,000. Finally, Hillsdale Investment Management Inc. bought a new stake in shares of Alimera Sciences in the 1st quarter valued at about $169,000. Institutional investors own 99.83% of the company’s stock.

About Alimera Sciences

Alimera Sciences, Inc, a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).